MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
OTCMQB
0.920
+0.050
+5.74%
Opening 11:18 09/24 EDT
OPEN
0.880
PREV CLOSE
0.870
HIGH
1.080
LOW
0.880
VOLUME
11.64K
TURNOVER
11.62K
52 WEEK HIGH
6.30
52 WEEK LOW
0.465
MARKET CAP
10.15M
P/E (TTM)
-0.9647
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCLI last week (0914-0918)?
Weekly Report · 3d ago
Weekly Report: what happened at BCLI last week (0907-0911)?
Weekly Report · 09/14 09:33
Weekly Report: what happened at BCLI last week (0831-0904)?
Weekly Report · 09/07 09:31
Weekly Report: what happened at BCLI last week (0824-0828)?
Weekly Report · 08/31 09:34
BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
PR Newswire · 08/24 12:15
Weekly Report: what happened at BCLI last week (0817-0821)?
Weekly Report · 08/24 09:34
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Brainstorm Cell Therapeutics (OtherBCLI) and Edwards Lifesciences (EW)
TipRanks · 08/18 20:20
Weekly Report: what happened at BCLI last week (0810-0814)?
Weekly Report · 08/17 09:34
More
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Webull offers Brainstorm Cell Therapeutics Inc stock information, including OTCMQB: BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.